European regulators have finally approved the Alzheimer's treatment Leqembi after an advisory committee initially rejected the drug last summer.

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three buildings to one.

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...

As part of a bid to consolidate its footprint in Massachusetts, Biogen is foregoing its old home base to put down new roots in Cambridge. That said, the company won’t be moving far from its ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and then, ...

Cambridge-based biotech Biogen Idec, the maker of the multiple sclerosis drug Tysabri, linkurl:announced;http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol ...

Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

As an independent biotechnology company, Biogen (Cambridge, MA) has led innovation in treatment and outcomes assessment in MS for >25 years and continues to have an enduring commitment to elevate ...